( hout causing anyobservable toxicity. T...)Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies,Health

hout causing any observable toxicity. The studies also showed that different forms of the VTAs could be combined, and that the combination of 2aG4-IL-2 with 2aG4-alpha interferon was significantly more effective in inhibiting tumor growth than either agent alone. In a preclinical model of B-cell lymphoma, tumor growth was inhibited by 85% in the combination-treated group compared with 60% and 65% in animals treated with either 2aG4-IL-2 or 2aG4-alpha interferon, respectively.

"These new data reaffirm the broad potential and versatility of our Vascular Targeting Agent platform for cancer therapy," said Steven W. King, president and CEO of Peregrine. "We have long thought that our anti- phospholipid antibodies would be ideal for the delivery of cytokines for cancer therapy based on their inherent immunostimulatory effects combined with the anti-tumor effects of the cytokines themselves. We are especially pleased with the strong anti-tumor activity observed in a model of B-cell lymphoma, the first non-solid cancer we have successfully addressed using our VTA technology. We are now assessing our options to further develop and commercialize these cytokine fusion proteins for cancer and potentially, viral infections."

The new class of fusion protein agents falls under Peregrine's VTA technology platform for cancer therapy that includes over 200 patents and patent applications covering broad concepts of tumor therapy using agents that target tumor blood vessels. Because interferon is currently part of standard- of-care therapy for virus infections including chronic hepatitis C, Peregrine also intends to assess the utility of the new class as a second-generation treatment for viral infections.

This work was supported by Susan G. Komen for the Cure and a sponsored research agreement with Peregrine Pharmaceuticals Inc.

Number 3539: Inhibition of Tumor Growth by Targeting Cytokines to Phosphatidylserine (PS) on Tumor Vascular Endothelium, Xianming H
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes